Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer

Melinda M. Mortenson; Michael G. Schlieman; Subbulakshmi Virudachalam; Primo N Lara; David R Gandara; Angela M. Davies; Richard J Bold

doi:10.1016/j.lungcan.2005.01.006

Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer

Melinda M. Mortenson, Michael G. Schlieman, Subbulakshmi Virudachalam, Primo N Lara, David R Gandara, Angela M. Davies, Richard J Bold

Research output: Contribution to journal › Article › peer-review

42 Scopus citations

Abstract

Overexpression of the anti-apoptotic protein BCL-2 is frequently observed in small cell lung cancers (SCLC) and is associated with chemoresistance. We examined the signaling pathways involved in upregulation of BCL-2 in SCLC, and whether inhibition of NF-κB using the 26S proteasome inhibitor bortezomib had any effect on BCL-2 levels or apoptosis. Mutation of a NF-κB site in the BCL-2 promoter reduced promoter activity to less than 20% of the wild-type promoter. Treatment with bortezomib resulted in decreased transcription of the BCL-2 promoter, decreased BCL-2 levels, and induced apoptosis. These data provide the necessary laboratory background for further investigation of bortezomib in the treatment of SCLC.

Original language	English (US)
Pages (from-to)	163-170
Number of pages	8
Journal	Lung Cancer
Volume	49
Issue number	2
DOIs	https://doi.org/10.1016/j.lungcan.2005.01.006
State	Published - Aug 2005

Keywords

BCL-2
Bortezomib
NF-κB
SCLC

ASJC Scopus subject areas

Oncology

Access to Document

10.1016/j.lungcan.2005.01.006

Cite this

Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer. / Mortenson, Melinda M.; Schlieman, Michael G.; Virudachalam, Subbulakshmi; Lara, Primo N ; Gandara, David R; Davies, Angela M.; Bold, Richard J.

In: Lung Cancer, Vol. 49, No. 2, 08.2005, p. 163-170.

Research output: Contribution to journal › Article › peer-review

@article{74da4f194c484a05878b65c7d29ab4db,

title = "Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer",

abstract = "Overexpression of the anti-apoptotic protein BCL-2 is frequently observed in small cell lung cancers (SCLC) and is associated with chemoresistance. We examined the signaling pathways involved in upregulation of BCL-2 in SCLC, and whether inhibition of NF-κB using the 26S proteasome inhibitor bortezomib had any effect on BCL-2 levels or apoptosis. Mutation of a NF-κB site in the BCL-2 promoter reduced promoter activity to less than 20% of the wild-type promoter. Treatment with bortezomib resulted in decreased transcription of the BCL-2 promoter, decreased BCL-2 levels, and induced apoptosis. These data provide the necessary laboratory background for further investigation of bortezomib in the treatment of SCLC.",

keywords = "BCL-2, Bortezomib, NF-κB, SCLC",

author = "Mortenson, {Melinda M.} and Schlieman, {Michael G.} and Subbulakshmi Virudachalam and Lara, {Primo N} and Gandara, {David R} and Davies, {Angela M.} and Bold, {Richard J}",

year = "2005",

month = aug,

doi = "10.1016/j.lungcan.2005.01.006",

language = "English (US)",

volume = "49",

pages = "163--170",

journal = "Lung Cancer",

issn = "0169-5002",

publisher = "Elsevier Ireland Ltd",

number = "2",

}

TY - JOUR

T1 - Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer

AU - Mortenson, Melinda M.

AU - Schlieman, Michael G.

AU - Virudachalam, Subbulakshmi

AU - Lara, Primo N

AU - Gandara, David R

AU - Davies, Angela M.

AU - Bold, Richard J

PY - 2005/8

Y1 - 2005/8

N2 - Overexpression of the anti-apoptotic protein BCL-2 is frequently observed in small cell lung cancers (SCLC) and is associated with chemoresistance. We examined the signaling pathways involved in upregulation of BCL-2 in SCLC, and whether inhibition of NF-κB using the 26S proteasome inhibitor bortezomib had any effect on BCL-2 levels or apoptosis. Mutation of a NF-κB site in the BCL-2 promoter reduced promoter activity to less than 20% of the wild-type promoter. Treatment with bortezomib resulted in decreased transcription of the BCL-2 promoter, decreased BCL-2 levels, and induced apoptosis. These data provide the necessary laboratory background for further investigation of bortezomib in the treatment of SCLC.

AB - Overexpression of the anti-apoptotic protein BCL-2 is frequently observed in small cell lung cancers (SCLC) and is associated with chemoresistance. We examined the signaling pathways involved in upregulation of BCL-2 in SCLC, and whether inhibition of NF-κB using the 26S proteasome inhibitor bortezomib had any effect on BCL-2 levels or apoptosis. Mutation of a NF-κB site in the BCL-2 promoter reduced promoter activity to less than 20% of the wild-type promoter. Treatment with bortezomib resulted in decreased transcription of the BCL-2 promoter, decreased BCL-2 levels, and induced apoptosis. These data provide the necessary laboratory background for further investigation of bortezomib in the treatment of SCLC.

KW - BCL-2

KW - Bortezomib

KW - NF-κB

KW - SCLC

UR - http://www.scopus.com/inward/record.url?scp=22044440019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22044440019&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2005.01.006

DO - 10.1016/j.lungcan.2005.01.006

M3 - Article

C2 - 16022909

AN - SCOPUS:22044440019

VL - 49

SP - 163

EP - 170

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 2

ER -

Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this